Kicker Ventures Joins Kanvas Biosciences' $48 Million Series A Round to Advance Microbiome Medicine
NQ Score
86/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Kicker Ventures, a US-based venture capital firm, has announced its participation in a $48 million Series A funding round for Kanvas Biosciences, a Princeton, NJ-based biotechnology company. This investment will support Kanvas Biosciences' development of microbiome-based therapies for conditions such as cancer immunotherapy, colitis associated with immune checkpoint inhibitors, and malnutrition-related gut dysfunction.